Kuidas hirmu- või murega toime tulla?
Nõustamisjuhend, kuidas toetada ennast ja oma lähedasi
Saadaval lugemiseks iOS-is, Androidis, PC-s ja Mac-is, E-lugerites ja tahvelarvutite seadmetes.
Pikkus: 31 slaidiga video
Formaat: PDF + MP4 videoheli fail
Koroonaviiruse viirusevastane ravim avastati Leuvenis 15 aastat tagasi. Siit leiad uusima teabe COVID-19 juhtumite kohta. Haigusjuhtumeid on avastatud Aasias, aga ka Aafrikas, Austraalias, Euroopas ja Põhja-Ameerikas.
Following the first reports of cases of acute respiratory syndrome in the Chinese Wuhan municipality at the end of December 2019, Chinese authorities have identified a novel coronavirus as the main causative agent. The outbreak has rapidly evolved affecting other parts of China and outside the country. Cases have been detected in several countries in Asia, but also in Australia, Europe, Africa and North America. The first cases in the EU/EEA were confirmed in France. Further global spread is likely.
On 12 February 2020, the novel coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while the disease associated with it is now referred to as COVID-19. It is a new strain of coronavirus that has not been previously identified in humans. Outbreaks of novel virus infections among people are always of public health concern, especially when there’s little knowledge about the characteristics of the virus, how it spreads between people, how severe are the resulting infections and how to treat them.
Human-to-human transmission has been confirmed but more information is needed to evaluate the full extent of this mode of transmission. The source of infection is unknown and could still be active.
This is an emerging, rapidly evolving situation with ongoing outbreak investigations. ECDC is closely monitoring this outbreak and providing risk assessments to guide EU Member States and the EU Commission in their response activities.